← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Other immunostimulants
pegademase
L03AX04
Forms & Strengths
- Injection: 1.4 mL vial containing 1.1 mg of pegademase bovine
- Lyophilized powder for reconstitution
Adult Dosing
- 10-20 U/kg IV every 2 weeks
- Titrate dose to maintain adequate deoxyadenosine triphosphate (dATP) levels
Pediatric Dosing
- Initial dose: 10 U/kg IV every 2 weeks
- Titrate dose based on erythrocyte dATP levels
Indications
- Treatment of severe combined immunodeficiency disease (SCID) associated with adenosine deaminase (ADA) deficiency
- ADA-SCID with impaired immune function
Mechanism of Action
- Catalyzes the conversion of adenosine and deoxyadenosine to inosine and deoxyinosine
- Reduces toxic levels of deoxyadenosine triphosphate (dATP) in cells
- Restores lymphocyte function and immune competence
Contraindications
- Hypersensitivity to pegademase bovine or other bovine-derived products
Adverse Reactions
- Hematoma or bleeding at injection site
- Headache
- Fevers
- Chills
- Muscle or joint pain
Drug Interactions
- Incompatible with other drugs or infusion solutions
- Avoid concurrent administration with blood products or other IV solutions
Curated Content: Needs Vetting Before Put to Clinical Use